Marine Compounds as Anti-Alzheimer's Agent

Dear Colleagues,

Alzheimer’s disease is the most common progressive neurodegenerative disorder and the major cause of dementia. The main pathological hallmarks of AD include extracellular deposition of amyloid plaque, intraneuronal aggregation of neurofibrillary tangles, and brain atrophy. The therapeutic strategy of AD requires a multitargeted approach because of its multifaceted pathobiology. Oxidative stress, neuroinflammation, and an impaired protein clearance system constitute primary contributing factors in the pathogenesis of AD and can therefore be potential targets for the development of anti-AD agents. Although synthetic and semisynthetic drugs are the primary source of therapeutics against AD, their adverse side effects have led researchers to search for therapeutic leads from natural compounds. Diverse marine organisms are offering a wonderful source of natural compounds. Marine natural products are shown to be effective in attenuating AD pathobiological processes. Many of these compounds modulate various molecular targets of brain-specific biochemical and signaling pathways, suggesting their therapeutic significance in the management of neurodegenerative disorders, including AD. Natural product researchers and drug designers have been focusing their attention on the discovery and development of novel therapeutic leads from marine natural products or their skeleton.

This Special Issue will cover the identification and characterization of novel compounds from marine organisms, the bioactivity of already known molecules, structure-activity relationship, strategies for brain delivery, and the mechanism of neuroprotection against various toxic insults representing in vitro and in vivo models of AD. Both original research and review papers are welcome.

Prof. Dr. II Soo Moon
Prof. Dr. Md Abdul Hannan 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• marine natural products
• identification and characterization of marine compounds and their structure-activity relationships
• mechanistic insights through experimental and bioinformatics approaches
• antioxidant, anti-inflammatory, anti-cholinesterase, and anti-amyloid properties
• nano-guided drug delivery
• neuroprotection
• Alzheimer’s disease and associated complications, such as diabetes-induced cognitive deficits